Table 1 Clinical characteristics of patients receiving lenvatinib.
Characteristics | |
|---|---|
Total number | 40 |
Female:Male | 27:13 |
Age (years) | 63.0 ± 10.9 (33–78) |
Body weight (kg) | 56.0 ± 11.0 (35–82) |
Laboratory test values at lenvatinib initiation | |
Aspartate transaminase (IU/L) | 25.9 ± 8.9 (13–56) |
Alanine transaminase (IU/L) | 22.3 ± 9.1 (11–45) |
Serum albumin (g/dL) | 3.9 ± 0.5 (2.7–5.1) |
Total bilirubin (mg/dL) | 0.6 ± 0.2 (0.4–1.5) |
Serum creatinine (mg/dL) | 0.76 ± 0.29 (0.41–1.78) |
ABCB1 1236C > T | C/C: C/T: T/T = 8: 22: 10 |
ABCB1 2677G > T/A | G/G: G/T: G/A: T/T: T/A: A/A = 9: 15: 4: 4: 5: 3 |
ABCB1 3435C > T | C/C: C/T: T/T = 14: 21: 5 |
ABCG2 421C > A | C/C: C/A: A/A = 20: 18: 2 |
ABCC2 −24C > T | C/C: C/T: T/T = 24: 14: 2 |
CYP3A4 20230 G > A(*1G) | *1/*1: *1/*1G: *1G/*1G = 24: 15: 1 |
CYP3A5 6986 A > G(*3) | *1/*1: *1/*3: *3/*3 = 1: 13: 26 |
